Ebastine for Adjuvant Treatment of Tumor Budding-Positive Liver Cancer After Surgery

Official record

Identifier

NCT07734766

Recruiting locations

Locations are not included in the offline baseline for this record. Open the official record to see the current site list.

Interventions studied

Ebastine

Lead sponsor

Second Affiliated Hospital of Xi'an Jiaotong University

Target enrolment

45 participants

Study type

INTERVENTIONAL

Phase

Phase 4

Status

Not yet recruiting

First posted

Jul 29, 2026

Last updated on the registry

Jul 29, 2026

Age

18 Years

Sex

ALL

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* Age is ≥18 years old, male or female;
* Histologically confirmed as hepatocellular carcinoma without metastasis;
* Tumor budding is positive
* Life expectancy of at least 12 weeks;

Exclusion Criteria:

* Hepatocellular carcinoma that cannot be surgically resected
* Received radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc. before surgery
* Pregnant or lactating women
* Subjects with other malignant tumors;
* Subjects who are considered unsuitable to participate in this cohort study by the investigator;
* Subjects who refuse to enroll or do not sign the informed consent form;
* Subjects with incomplete medical record information (including gender, age, diagnostic information, imaging (and) or pathological diagnosis results, other demographic data, etc.).

Indexed under

Liver Cancer